Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Monitoring of KRAS-mutated ctDNA to discriminate pseudo-progression from true progression during anti-PD-1 treatment of lung adenocarcinoma

7 Apr 2017

Abstract excerpt

// Nicolas Guibert 1,2,4 , Julien Mazieres 1,2,4 , Myriam Delaunay 1,2,4 , Anne Casanova 2,3 , Magali Farella 2,3 , Laura Keller 2,3 , Gilles Favre 2,3,4 and Anne Pradines 2,3 1 Thoracic Oncology Department, Larrey Hospital, University Hospital of Toulouse, Toulouse, France 2 Inserm, Centre de Recherche en Cancérologie de Toulouse, CRCT UMR-1037, Toulouse, France 3 Institut Claudius Regaud, IUCT-Oncopole,...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer Genomics and Diagnostics
Share to Cancer Immunotherapy and Biomarkers
Share to Lung Cancer Treatments and Mutations

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Source

Identifiers

PMID: 28445137
DOI: 10.18632/oncotarget.16935

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 13 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 10 closest

Monitoring of KRAS-mutated ctDNA to discriminate pseudo-progression from true progression during anti-PD-1 treatment of lung adenocarcinomaPMID 28445137Read ↗

Pseudoprogression in Immunotherapy and Identification of Clinical-Biologic Predictive Factors: A Retrospective Pan-Tumor Cohort StudySemantic proximity Read ↗

Investigation of transrenal KRAS mutation in late stage NSCLC patients correlates to disease progression.Semantic proximity Read ↗

Early assessment of KRAS mutation in cfDNA correlates with risk of progression and death in advanced non-small-cell lung cancer.Semantic proximity Read ↗

Plasma EGFR T790M ctDNA status is associated with clinical outcome in advanced NSCLC patients with acquired EGFR-TKI resistance.Semantic proximity Read ↗

ctDNA Detection of Polyclonal KRAS Resistance in Adagrasib-Treated NSCLC.Semantic proximity Read ↗

Very early response of circulating tumour-derived DNA in plasma predicts efficacy of nivolumab treatment in patients with non-small cell lung cancer.Semantic proximity Read ↗

Early Changes in Circulating Cell-Free KRAS G12C Predict Response to Adagrasib in KRAS Mutant Non-Small Cell Lung Cancer Patients.Semantic proximity Read ↗

Monitoring the effect of first line treatment in RAS/RAF mutated metastatic colorectal cancer by serial analysis of tumor specific DNA in plasma.Semantic proximity Read ↗

Detection of ALK and KRAS Mutations in Circulating Tumor DNA of Patients With Advanced ALK-Positive NSCLC With Disease Progression During Crizotinib Treatment.Semantic proximity Read ↗

The Clinical Impact of Re-biopsies in Lung Adenocarcinoma: a Retrospective Multicenter Study.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.